Epredia has been appointed as a global distribution partner for Aiforia’s portfolio of preclinical and clinical pathology tools, including segment exclusivity for distribution in the United States.
Read More
To identify and treat COVID-19 patients at an early stage, predictive biomarkers need to be identified; researchers have discovered one.
Read More
Researchers have developed a blood test that uses cell-free DNA to gauge the damage that covid-19 inflicts on cells, tissues, and organs, and could help aid in the development of new therapies.
Read More
Engineered recombinant antibodies offer advantages over serum-based controls.
Read More
The tissue-based comprehensive genomic profiling test is currently approved as a companion diagnostic for more than 20 targeted therapies.
Read More